30.11.2016
Evotec AG DE0005664809
DGAP-News: EVOTEC AND MERCK ENTER INTO AGREEMENTS TO COLLABORATE ON TARGET DISCOVERY TECHNOLOGIES
DGAP-News: Evotec AG / Key word(s): Alliance
EVOTEC AND MERCK ENTER INTO AGREEMENTS TO COLLABORATE ON TARGET DISCOVERY
TECHNOLOGIES
30.11.2016 / 07:30
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
- Collaboration on a validated CRISPR platform and Merck's extensive
genomic toolkits beyond CRISPR
- Integration of Evotec's expertise on phenotypic screening and disease
biology
Hamburg, Germany, 30 November 2016:
Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) today
announced the signing of a set of collaboration agreements with the life
science business of Merck, which will combine Merck's portfolio of genome
editing technologies with Evotec's versatile screening platforms and
disease expertise. Evotec will leverage Merck's comprehensive collection of
genetic reagents such as viral CRISPR and shRNA libraries to enable new
target discovery programmes using its capabilities for phenotypic screening
in primary and induced pluripotent stem ("iPS") cells, as well as its in
vivo disease models. Bringing together the complementary offerings, the two
companies aim to provide fast and validated workflows to clients seeking to
explore a new target space within complex disease models.
Dr Mario Polywka, Chief Operating Officer of Evotec, commented: "Together
with our recent licensing of the CRISPR-Cas9 gene editing technology, these
agreements with Merck further strengthen Evotec's offering in the area of
target identification and validation for our partners. Deploying Merck's
assay-ready reagents on our cellular screening platforms and in vivo models
creates powerful capabilities in the area of target ID. With this we
provide more value to joint clients by a one-stop-shop solution for this
innovative drug discovery segment."
"The life science business of Merck has always been a leader in the
development and distribution of functional genomics reagents, like CRISPR
and shRNA", said Theresa S. Creasey, Head of Applied Solutions Strategic
Marketing & Innovation at Merck. "Our Cell Design Studio team has been
making custom cell lines for drug discovery for a decade, so this is an
area where we are strong. What we were missing was a collaborator that
could apply these reagents and cell lines for our customers, creating a
full service, one-stop solution. Working with an expert in this field like
Evotec completes our offering."
ABOUT EVOTEC AG
Evotec is a drug discovery alliance and development partnership company
focused on rapidly progressing innovative product approaches with leading
pharmaceutical and biotechnology companies, academics, patient advocacy
groups and venture capitalists. We operate worldwide providing the highest
quality stand-alone and integrated drug discovery solutions, covering all
activities from target-to-clinic to meet the industry's need for innovation
and efficiency in drug discovery (EVT Execute). The Company has established
a unique position by assembling top-class scientific experts and
integrating state-of-the-art technologies as well as substantial experience
and expertise in key therapeutic areas including neuroscience, diabetes and
complications of diabetes, pain and inflammation, oncology and infectious
diseases. On this basis, Evotec has built a broad and deep pipeline of more
than 70 partnered product opportunities at clinical, pre-clinical and
discovery stages (EVT Innovate). Evotec has established multiple long-term
discovery alliances with partners including Bayer, CHDI, Sanofi or UCB and
development partnerships with e.g. Janssen Pharmaceuticals in the field of
Alzheimer's disease, with Sanofi in the field of diabetes and with Pfizer
in the field of tissue fibrosis. For additional information please go to
www.evotec.com.
FORWARD LOOKING STATEMENTS
Information set forth in this press release contains forward-looking
statements, which involve a number of risks and uncertainties. The
forward-looking statements contained herein represent the judgement of
Evotec as of the date of this press release. Such forward-looking
statements are neither promises nor guarantees, but are subject to a
variety of risks and uncertainties, many of which are beyond our control,
and which could cause actual results to differ materially from those
contemplated in these forward-looking statements. We expressly disclaim any
obligation or undertaking to release publicly any updates or revisions to
any such statements to reflect any change in our expectations or any change
in events, conditions or circumstances on which any such statement is
based.
Contact Evotec AG:
Gabriele Hansen, VP Corporate Communications & Investor Relations, Phone:
+49.(0)40.56081-255, [email protected]
---------------------------------------------------------------------------
30.11.2016 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Evotec AG
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
Phone: +49 (0)40 560 81-0
Fax: +49 (0)40 560 81-222
E-mail: [email protected]
Internet: www.evotec.com
ISIN: DE0005664809
WKN: 566480
Indices: TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover,
Munich, Stuttgart, Tradegate Exchange
End of News DGAP News Service
---------------------------------------------------------------------------
525345 30.11.2016
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
Evotec AG ISIN: DE0005664809 können Sie bei EQS abrufen
Biotechnologie , 566480 , EVT , XETR:EVT